Provider review
Noom Med tirzepatide review
What Noom Med charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on Noom Med’s own pages on November 20, 2026: GLP-1Rx Plus (compounded tirzepatide): $149 for the first 4 weeks, then $299 a month, billed $897 every 12 weeks. It scores 45/100 under our written v4.1 scoring guide, #20 of 22 programs scored.
What is distinctive about this programme
A dose cap is not a discount
This is the clearest instance in our dataset of a pricing structure that requires explanation rather than comparison. Noom Med's $199 semaglutide programme is capped at a 0.6 mg maximum dose. The STEP trials that established semaglutide's weight-management efficacy used 2.4 mg.
A capped programme is not a cheaper version of the same treatment. It is a lower-dose treatment with a correspondingly smaller expected effect, and it should not appear in the same price ranking as full-titration programmes. Noom's own full-titration programme is $279, which is the figure that belongs in a like-for-like comparison.
We have kept the capped programme out of our cheapest-by-definition table for exactly this reason.
Introductory pricing and quarterly billing
The first month is $149 for tirzepatide against $299 ongoing. Introductory rates are excluded from every ranking on this site.
Quarterly billing sits between month-to-month and prepaid: less commitment than twelve months, less flexibility than monthly, and a three-month exposure if you stop.
Where the full programmes sit
At $279 semaglutide and $299 tirzepatide, Noom's full-titration programmes are in the upper band of the compounded market. Brand Zepbound is $299 direct from LillyDirect, and the approved oral orforglipron is $149 — both FDA-approved products at or below Noom's compounded tirzepatide price.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $199 | Provider-reported |
| Tirzepatide injectable | $299 | Provider-reported |
Where it holds up
- Publishes both a capped and a full-titration option rather than only the cheaper one
- Quarterly billing is a middle path between monthly and annual commitment
- Established consumer platform with an existing behavioural programme
Where it does not
- The $199 programme is capped at 0.6 mg, well below the trial dose
- Full-titration pricing is in the upper band of the compounded market
- Compounded tirzepatide at $299 matches brand Zepbound's manufacturer-direct starter price
- First-month rates are introductory
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $199/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Noom Med | prepaid | compounded injectable | not recorded | $299 | not verified | $299 | Commitment tier | Provider-reported | 2026-07-06 |
| Noom Med | prepaid | compounded injectable | not recorded | $199 | not verified | $199 | Commitment tier | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Noom Med sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is Noom Med the cheapest option?
Read on its own page on November 20, 2026: GLP-1Rx Plus (compounded tirzepatide): $149 for the first 4 weeks, then $299 a month, billed $897 every 12 weeks; clinical care and the app included.
Is compounded tirzepatide the same as Zepbound?
Noom Med scores 45/100 under the written v4.1 scoring guide, #20 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is pharmacy transparency (0 of 15).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Open GLP-1 Data and Evidence LibraryData
- Oak Longevity Tirzepatide ReviewProviders
- NexLife vs Henry MedsComparisons
Related coverage
- NexLife Tirzepatide Review
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Cheapest FDA-Approved vs Compounded GLP-1 Options
- If Your Compounded GLP-1 Supply Ends: A Practical Transition Plan
- Compounded vs Brand Tirzepatide: Legal and Evidence Differences
- How Dose Escalation Changes Tirzepatide Cost
- FDA Compounded GLP-1 Rules in 2026
- How to Spot Fraudulent Compounded GLP-1 Labels
GLP-1 Tirzepatide Review. “Noom Med Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/noom-med/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.